OptiNose
- Country
- 🇳🇴Norway
- Ownership
- Public
- Established
- 2000-01-01
- Employees
- 132
- Market Cap
- $155.3M
- Website
- http://www.optinose.com
- Introduction
OptiNose, Inc. operates as a pharmaceutical company. The firm engages in the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. Its products include the XHANCE and ONZETRA Xsail. The company was founded by Per Gisle Djupesland and Helena Kyttari Djupesland in October 2000 and is headquartered in Yardley, PA.
Clinical Trials
13
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (13 trials with phase data)• Click on a phase to view related trials
Efficacy and Safety of 186 mcg of OPN-375 Nasal Spray Twice a Day (BID) in Adolescents With Chronic Rhinosinusitis Without Nasal Polyps
- Conditions
- Chronic Rhinosinusitis Without Nasal Polyps
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-02-27
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- Optinose US Inc.
- Target Recruit Count
- 84
- Registration Number
- NCT06850805
- Locations
- 🇺🇸
San Tan Allergy & Asthma, Gilbert, Arizona, United States
🇺🇸Children's Hospital of Orange County, Orange, California, United States
🇺🇸DaVinci Research, LLC, Sacramento, California, United States
A Study to Evaluate Change in Viral Load After OPN-019 in Adults With COVID-19
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2022-05-02
- Lead Sponsor
- Optinose US Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT05035576
- Locations
- 🇲🇽
Fundacion Santos y de la Garza Evia, I.B.P, Monterrey, N.l., Mexico
Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis Without the Presence of Nasal Polyps
- First Posted Date
- 2019-05-23
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- Optinose US Inc.
- Target Recruit Count
- 223
- Registration Number
- NCT03960580
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Sacramento Ear, Nose & Throat Surgical and Medical Group Inc, Folsom, California, United States
🇺🇸BioSolutions Clinical Research Center, La Mesa, California, United States
Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis With or Without the Presence of Nasal Polyps
- First Posted Date
- 2018-12-20
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Optinose US Inc.
- Target Recruit Count
- 332
- Registration Number
- NCT03781804
- Locations
- 🇺🇸
AZ Allergy & Immunology Research, Gilbert, Arizona, United States
🇺🇸Kern Research, Bakersfield, California, United States
🇺🇸Sacramento Ear, Nose & Throat Surgical and Medical Group Inc, Folsom, California, United States
OPN-375 Efficacy and Safety in Adolescents With Bilateral Nasal Polyps
- First Posted Date
- 2018-11-20
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- Optinose US Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT03747458
- Locations
- 🇺🇸
Clinical Research Center of Alabama, Birmingham, Alabama, United States
🇺🇸Arizona Allergy and Immunology Research, Gilbert, Arizona, United States
🇺🇸San Tan Allergy & Asthma, Gilbert, Arizona, United States
- Prev
- 1
- 2
- 3
- Next
News
Paratek Pharmaceuticals Acquires Optinose for $330 Million to Expand XHANCE Access in Chronic Rhinosinusitis Market
Paratek Pharmaceuticals announced the acquisition of Optinose for up to $330 million, gaining access to XHANCE, the first and only approved treatment for chronic rhinosinusitis with or without nasal polyps.